ATE352307T1 - Zusammensetzung zur behandlung von tumoren oder krebs, welche fluorouracil und ein methylol übertragungsmittel enthält - Google Patents
Zusammensetzung zur behandlung von tumoren oder krebs, welche fluorouracil und ein methylol übertragungsmittel enthältInfo
- Publication number
- ATE352307T1 ATE352307T1 AT01309983T AT01309983T ATE352307T1 AT E352307 T1 ATE352307 T1 AT E352307T1 AT 01309983 T AT01309983 T AT 01309983T AT 01309983 T AT01309983 T AT 01309983T AT E352307 T1 ATE352307 T1 AT E352307T1
- Authority
- AT
- Austria
- Prior art keywords
- transfer agent
- tumors
- treatment
- composition
- methylol transfer
- Prior art date
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229960002949 fluorouracil Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004267 taurolidine Drugs 0.000 abstract 1
- 229950007343 taurultam Drugs 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25313800P | 2000-11-28 | 2000-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE352307T1 true ATE352307T1 (de) | 2007-02-15 |
Family
ID=22959032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01309983T ATE352307T1 (de) | 2000-11-28 | 2001-11-28 | Zusammensetzung zur behandlung von tumoren oder krebs, welche fluorouracil und ein methylol übertragungsmittel enthält |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020111328A1 (enExample) |
| EP (1) | EP1208840B1 (enExample) |
| JP (2) | JP2002326936A (enExample) |
| AT (1) | ATE352307T1 (enExample) |
| CA (1) | CA2363973C (enExample) |
| DE (1) | DE60126225T2 (enExample) |
| ES (1) | ES2278702T3 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8304390B2 (en) | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US7345039B2 (en) | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US6753328B2 (en) * | 2001-10-01 | 2004-06-22 | Rhode Island Hospital | Methods of inhibiting metastases |
| US20100151004A1 (en) * | 2007-03-07 | 2010-06-17 | University Of Medicine And Dentistry Of New Jersey | Modulation of drug sensitivity |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| CN113347976A (zh) * | 2018-08-28 | 2021-09-03 | 科医公司 | 用牛磺罗定水解产物进行的神经母细胞瘤治疗 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
-
2001
- 2001-11-26 CA CA002363973A patent/CA2363973C/en not_active Expired - Fee Related
- 2001-11-27 JP JP2001361167A patent/JP2002326936A/ja active Pending
- 2001-11-27 US US09/993,896 patent/US20020111328A1/en not_active Abandoned
- 2001-11-28 AT AT01309983T patent/ATE352307T1/de not_active IP Right Cessation
- 2001-11-28 EP EP01309983A patent/EP1208840B1/en not_active Expired - Lifetime
- 2001-11-28 DE DE60126225T patent/DE60126225T2/de not_active Expired - Lifetime
- 2001-11-28 ES ES01309983T patent/ES2278702T3/es not_active Expired - Lifetime
-
2009
- 2009-10-09 JP JP2009235501A patent/JP2010043115A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010043115A (ja) | 2010-02-25 |
| JP2002326936A (ja) | 2002-11-15 |
| CA2363973A1 (en) | 2002-05-28 |
| DE60126225D1 (de) | 2007-03-15 |
| DE60126225T2 (de) | 2007-10-11 |
| ES2278702T3 (es) | 2007-08-16 |
| US20020111328A1 (en) | 2002-08-15 |
| CA2363973C (en) | 2009-03-10 |
| EP1208840A2 (en) | 2002-05-29 |
| EP1208840B1 (en) | 2007-01-24 |
| EP1208840A3 (en) | 2003-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1292594E (pt) | Derivados de quinazolina para o tratamento de tumores | |
| ATE527250T1 (de) | 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs | |
| ATE466885T1 (de) | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust | |
| DE60216139D1 (de) | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen | |
| DE60024360D1 (de) | Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) | |
| ATE556713T1 (de) | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer | |
| DE60118547D1 (de) | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE409185T1 (de) | Chinazolin derivate | |
| ATE236147T1 (de) | Derivate von flavonen, xanthonen und kumarinen | |
| DE60126225D1 (de) | Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält | |
| DE69927688D1 (de) | Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| BR0207443A (pt) | Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina | |
| NO20050428L (no) | Arylkarbonylpiperaziner og heteroarylkarbonylpiperaziner og anvendelse derav for behandling av godartede og ondartede tumorsykdommer | |
| EE200000472A (et) | Kasvajavastased toimeained | |
| ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| ATE456377T1 (de) | Behandlung des metastasierenden karzinoms der niere | |
| NO20023486L (no) | Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| EP1304111A3 (en) | Use of methylol-containing compounds for the treatment of breast cancer | |
| ATE429230T1 (de) | Chinazoline derivative und ihre anwendung in der krebsbehandlung | |
| DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |